Background: The goal of an intraoral radiograph is to be a valuable diagnostic tool while keeping the radiation exposure dose as low as reasonably achievable. The International Commission on Radiological Protection (ICRP) has strong recommendations for patient dose-reduction strategies.
Objective: To answer the following research question: 'In either patient or in phantoms, does rectangular collimation compared with other forms of collimation reduce the radiation absorbed dose during intraoral imaging?'
Methods: The search strategy was developed specifically for each electronic database. Information was collected from MEDLINE, all EBM Reviews including the Cochrane Library, EMBASE, LILACS, PubMed and Web of Science, and from a search of the grey literature via Google Scholar. Studies were included if they reported the radiation dose in intraoral imaging using rectangular collimation compared with any other type of collimation or the absence of it. Studies that did not involve comparison/control groups were excluded. A qualitative appraisal of the included studies was performed. The Methodological Index for NOn-Randomised Studies (MINORS) tool assessed the potential risk of bias among the studies, while the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach determined the level of available evidence.
Results: Thirteen studies using different types of receptors, including D-speed film, E-speed film, phosphor storage plates (PSP) and direct digital sensors, were included. Different methods to access absorbed and effective dose by exploring distinct technical parameters, such as distance object-receptor, long- and short-cone, kVp and mA, exposure time and beam filtering, were used. High heterogeneity between the studies was found. The level of evidence was classified as moderate. The radiation dose reduction ranged from 40% to 92% compared with circular collimation. The limitations of the cross-sectional design and in vivo studies were discussed. As this systematic review applied validated tools and guidelines designed for population-based studies, the application for studies based on computer simulations and dosimetry measurements was challenging.
Conclusion: There is moderate evidence suggesting that rectangular collimation significantly reduces radiation dose when compared with round collimation, justifying its implementation in clinical settings/private practices while taking intraoral radiographs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379043 | PMC |
http://dx.doi.org/10.1111/idj.12411 | DOI Listing |
Radiother Oncol
January 2025
Department of Nursing, Shanghai Proton and Heavy Ion Center, Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201315 China. Electronic address:
Background And Purpose: Few studies have examined the factors associated with xerostomia during proton and carbon ion radiotherapy for head and neck cancer (HNC), which are reported to have fewer toxic effects compared to traditional photon-based radiotherapy. This study aims to evaluate the performance of machine learning approaches in predicting grade 2 + xerostomia in adults with HNC receiving proton and carbon ion radiotherapy.
Materials And Methods: A retrospective study involving 1,769 adults with HNC who completed proton or carbon ion radiotherapy was conducted.
Background And Purpose: To develop a normal tissue complication probability (NTCP) model for predicting grade ≥ 2 acute oral mucositis (AOM) in head and neck cancer patients undergoing carbon-ion radiation therapy (CIRT).
Methods And Materials: We retrospectively included 178 patients, collecting clinical, dose-volume histogram (DVH), radiomics, and dosiomics data. Patients were randomly divided into training (70%) and test sets (30%).
Breast
January 2025
Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China; Shanghai Key Laboratory of Proton Therapy, Shanghai, 201801, China. Electronic address:
Purpose: This study aims to assess whether dual anti-HER2 therapy with trastuzumab and pertuzumab increases early cardiac toxicity compared to trastuzumab alone in breast cancer (BC) patients receiving postoperative radiation therapy (RT).
Methods: Consecutive operable BC patients receiving postoperative RT and trastuzumab with or without pertuzumab between January 2017 and September 2020 at seven tertiary hospitals in China were retrospectively reviewed. Cardiac examinations included echocardiography, electrocardiogram (ECG), NT-proBNP, and cTnI at baseline before RT and during the follow-up.
Eur J Radiol
December 2024
Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires St. Luc, Brussels, Belgium; Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), Brussels, Belgium. Electronic address:
Background: Ancillary breast cancer (BC) radiation therapy (RT), particularly associated with chemotherapy, increases the risk of coronary artery disease (CAD). However, it remains unclear whether this risk also applies to isolated contemporary radiotherapy without chemotherapy.
Methods: Seventy-five BC patients (35 left-sided and 40 right-sided) treated with RT and available dosimetry, prospectively underwent Agatston calcium score (CAC) and coronary CT angiography (CTCA) a median of 11 ± 1 years later and were compared to 75 age- and cardiovascular (CV) risk factor-matched female controls without a history of cancer.
Int J Radiat Oncol Biol Phys
January 2025
Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Purpose: Randomized trials have demonstrated similar local tumor control in patients treated with accelerated partial-breast irradiation (APBI) compared with whole-breast irradiation. However, the optimal APBI dose for maximizing tumor control and minimizing toxicity is uncertain.
Methods And Materials: We enrolled patients ≥18 years of age with grade 1 or 2 ductal carcinoma in situ or stage I invasive breast cancer and resection margins ≥2 mm between 2003 and 2011 to a sequential dose-escalation trial using 3-dimensional conformal external beam APBI giving twice daily 4 Gy fractions with total doses of 32 Gy, 36 Gy, and 40 Gy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!